# US 6,730,679 B1 · Pharmaceutical formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,679 B1
- Document ID: US6730679B1
- Status: Granted
- Kind: B1
- Application number: 08/820,848
- Filed: 1997-03-20
- Granted: 2004-05-04
- Earliest claimed: 1996-03-22
- Assignees: SmithKline Beecham Corporation
- Inventors: Arup K. Roy; Lloyd Gary Tillman
- Web page: https://patentgrep.com/patent/US6730679B1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/425: Thiazoles
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Pharmaceutical formulations containing HIV protease inhibitors, specifically including 3S-[3R*(1R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (alternatively known as VX 478 or 141W94), and a tocopherol, and their use in medical therapy are described.

## Claims

### Claim 1

A pharmaceutical formulation possessing unexpectedly enhanced bio-availability, comprising:
a) 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester,
b) a water soluble tocopherol derivative, and
(c) a hydrophilic non-aqueous solvent miscible with said water soluble tocopherol derivative.

### Claim 2 (depends on 1)

A pharmaceutical formulation as claimed in claim 1, comprising at least 20% of the water soluble tocopherol derivative.

### Claim 3 (depends on 1)

A pharmaceutical formulation as claimed in claim 1, wherein the ratio of (a) to (b) is from about 1:0.5 to about 1:3 w/w.

### Claim 4 (depends on 1)

A pharmaceutical formulation as claimed in claim 1, wherein the water soluble tocopherol derivative is Vitamin E-TPGS.

### Claim 5 (depends on 1)

A pharmaceutical formulation as claimed in claim 1, in the form of a capsule.

### Claim 6 (depends on 1)

A pharmaceutical formulation as claimed in claim 1, comprising 3S-[3R*(1R*, 2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester in an amount of about 10 to about 1500 mg.

### Claim 7 (depends on 1)

A pharmaceutical formulation as claimed in claim 1, wherein the hydrophillic non-aqueous solvent is a mixture of a polyethylene glycol and propylene glycol.

### Claim 8 (depends on 1)

A pharmaceutical formulation as claimed in claim 1, in the form of a solution.

### Claim 9 (depends on 1)

A pharmaceutical formulation as claimed in claim 1, comprising 3S-[3R*(1R*, 2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester in an amount of about 10 to about 1500 mg.

### Claim 10 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the water soluble tocopherol derivative is Vitamin E-TPGS.

### Claim 11

A pharmaceutical formulation, comprising:
a) 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl) propyl]carbamic acid, tetrahydro-3-furanyl ester,
b) from about 10% to about 60% w/w of a water soluble tocopherol derivative, and
(c) a hydrophilic non-aqueous solvent miscible with said water soluble tocopherol derivative,
wherein the ratio of (a) to (b) is from about 1:0.5 to about 1:10 w/w, and wherein said formulation possesses unexpectedly enhanced bioavailability.

### Claim 12 (depends on 11)

A pharmaceutical formulation as claimed in claim 11, in the form of a soft gelatin capsule.

### Claim 13

A pharmaceutical formulation, comprising:
(a) 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester,
(b) Vitamin E-TPGS,
(c) polyethylene glycol, and
(d) propylene glycol, and
wherein said formulation possesses unexpectedly enhanced bioavailability.

### Claim 14 (depends on 13)

A pharmaceutical formulation as claimed in claim 13, in the form of a soft gelatin capsule.

### Claim 15 (depends on 13)

The pharmaceutical formulation according to claim 13, which comprises from about 10% to about 60% w/w of Vitamin E-TPGS.

### Claim 16 (depends on 13)

The pharmaceutical formulation according to claim 13, wherein said formulation is a flowable liquid.

### Claim 17 (depends on 13)

The pharmaceutical formulation according to claim 13, wherein said formulation is formulated for oral administration.

### Claim 18

A pharmaceutical formulation, comprising:
(a) 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester in an amount from 1% to 50% w/w;
(b) a water soluble tocopherol derivative in an amount from about 10% to about 60% w/w; and
(c) a hydrophilic non-aqueous solvent miscible with the water soluble tocopherol derivative in an amount from about 15% to about 95%,
wherein, the hydrophilic non-aqueous solvent is a polyethylene glycol, propylene glycol, polyvinyl pyrrolidone, or a combination thereof; and
wherein said formulation possesses unexpectedly enhanced bioavailability.

### Claim 19 (depends on 18)

A pharmaceutical formulation according to claim 18, wherein the water soluble tocopherol derivative is Vitamin E-TPGS.

### Claim 20 (depends on 18)

The pharmaceutical formulation according to claim 18, wherein said formulation is in the form of a soft gelatin capsule.

### Claim 21

A pharmaceutical formulation for oral administration, comprising:
(a) about 19% w/w of 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester,
(b) about 51% w/w of Vitamin E-TPGS,
(c) about 25% w/w of polyethylene glycol, and
(d) about 5% w/w of propylene glycol, and
wherein said formulation possesses unexpectedly enhanced bioavailability.
